Does the media favor CGEM or ALEC?

In the previous week, Alector had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Alector and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.02 beat Alector's score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALEC or SPRY?

In the previous week, Alector had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Alector and 2 mentions for ARS Pharmaceuticals. Alector's average media sentiment score of 0.93 equaled ARS Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ALEC or MGTX?

MeiraGTx has higher revenue and earnings than Alector. MeiraGTx is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 9.36 -$142.93M -$1.19 N/A MeiraGTx $81.39M 10.68 -$114.20M -$1.48 N/A

Is ALEC or MGTX more profitable?

MeiraGTx has a net margin of -151.12% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat MeiraGTx's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% MeiraGTx -151.12% -1,065.47% -54.96%

Does the media refer more to ALEC or MGTX?

In the previous week, MeiraGTx had 8 more articles in the media than Alector. MarketBeat recorded 14 mentions for MeiraGTx and 6 mentions for Alector. MeiraGTx's average media sentiment score of 1.16 beat Alector's score of 0.93 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABUS or ALEC more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to Alector's net margin of -680.83%. Arbutus Biopharma's return on equity of 129.32% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% Alector -680.83% -295.17% -40.95%

Alector (ALEC) Competitors

$1.78 -0.18 (-8.97%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.01 (+0.34%)

As of 06:51 AM Eastern

Compare

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include Cullinan Therapeutics (CGEM), ARS Pharmaceuticals (SPRY), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

How does Alector compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

In the previous week, Alector had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Alector and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.02 beat Alector's score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cullinan Therapeutics' return on equity of -51.45% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Alector	-680.83%	-295.17%	-40.95%

Cullinan Therapeutics currently has a consensus target price of $30.75, suggesting a potential upside of 102.17%. Alector has a consensus target price of $3.63, suggesting a potential upside of 104.23%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alector has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Summary

Alector beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Alector compare to ARS Pharmaceuticals?

Alector (NASDAQ:ALEC) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Alector currently has a consensus price target of $3.63, suggesting a potential upside of 104.23%. ARS Pharmaceuticals has a consensus price target of $28.60, suggesting a potential upside of 226.86%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alector had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Alector and 2 mentions for ARS Pharmaceuticals. Alector's average media sentiment score of 0.93 equaled ARS Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.8% of Alector shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ARS Pharmaceuticals has a net margin of -200.00% compared to Alector's net margin of -680.83%. ARS Pharmaceuticals' return on equity of -153.61% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Alector has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Alector has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A
ARS Pharmaceuticals	$84.28M	10.31	-$171.30M	-$2.01	N/A

Summary

ARS Pharmaceuticals beats Alector on 9 of the 15 factors compared between the two stocks.

How does Alector compare to MeiraGTx?

Alector (NASDAQ:ALEC) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

MeiraGTx has a net margin of -151.12% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

85.8% of Alector shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 7.5% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alector presently has a consensus price target of $3.63, indicating a potential upside of 104.23%. MeiraGTx has a consensus price target of $25.83, indicating a potential upside of 175.12%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

MeiraGTx has higher revenue and earnings than Alector. MeiraGTx is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A
MeiraGTx	$81.39M	10.68	-$114.20M	-$1.48	N/A

In the previous week, MeiraGTx had 8 more articles in the media than Alector. MarketBeat recorded 14 mentions for MeiraGTx and 6 mentions for Alector. MeiraGTx's average media sentiment score of 1.16 beat Alector's score of 0.93 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Summary

MeiraGTx beats Alector on 11 of the 17 factors compared between the two stocks.

How does Alector compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Arbutus Biopharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

In the previous week, Alector had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Alector and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Alector's score of 0.93 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Alector	Positive

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 14.94%. Alector has a consensus price target of $3.63, suggesting a potential upside of 104.23%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Arbutus Biopharma has a net margin of 83.95% compared to Alector's net margin of -680.83%. Arbutus Biopharma's return on equity of 129.32% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Alector	-680.83%	-295.17%	-40.95%

Arbutus Biopharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arbutus Biopharma beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

In the previous week, Alector had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Alector and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.43 beat Alector's score of 0.93 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Positive
Alector	Positive

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Janux Therapeutics currently has a consensus target price of $45.85, indicating a potential upside of 237.35%. Alector has a consensus target price of $3.63, indicating a potential upside of 104.23%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Janux Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Janux Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Janux Therapeutics' return on equity of -12.93% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Alector	-680.83%	-295.17%	-40.95%

Janux Therapeutics has higher earnings, but lower revenue than Alector. Janux Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	82.87	-$113.62M	-$1.84	N/A
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

Summary

Janux Therapeutics beats Alector on 11 of the 17 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.50M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.49	17.78	22.17	24.18
Price / Sales	9.36	315.63	523.06	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	6.34	6.63	9.79	6.72
Net Income	-$142.93M	$24.20M	$3.57B	$337.19M
7 Day Performance	-17.44%	-4.39%	-2.49%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	14.52%	45.50%	26.49%	33.09%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	3.3816 of 5 stars	$1.78 -9.0%	$3.63 +104.2%	+19.9%	$216.50M	$21.05M	N/A	270	Insider Trade High Trading Volume
CGEM Cullinan Therapeutics	3.5102 of 5 stars	$16.44 +7.0%	$30.75 +87.0%	+69.8%	$944M	N/A	N/A	30	Positive News
SPRY ARS Pharmaceuticals	2.8486 of 5 stars	$9.07 -3.5%	$28.60 +215.3%	-39.8%	$933.45M	$84.28M	N/A	90	Analyst Upgrade
MGTX MeiraGTx	3.1934 of 5 stars	$10.66 +6.6%	$25.83 +142.5%	+69.5%	$926.10M	$79.76M	N/A	300	Positive News High Trading Volume
ABUS Arbutus Biopharma	2.2303 of 5 stars	$4.56 -0.9%	$5.00 +9.6%	+26.1%	$908.68M	$191.45M	5.49	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

How does Alector compare to Cullinan Therapeutics?

Summary

How does Alector compare to ARS Pharmaceuticals?

Summary

How does Alector compare to MeiraGTx?

Summary

How does Alector compare to Arbutus Biopharma?

Summary

How does Alector compare to Janux Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

How does Alector compare to Cullinan Therapeutics?

Does the media favor CGEM or ALEC?

Is CGEM or ALEC more profitable?

Do analysts recommend CGEM or ALEC?

Do institutionals and insiders have more ownership in CGEM or ALEC?

Which has stronger earnings and valuation, CGEM or ALEC?

Which has more risk & volatility, CGEM or ALEC?

Summary

How does Alector compare to ARS Pharmaceuticals?

Do analysts recommend ALEC or SPRY?

Does the media prefer ALEC or SPRY?

Do insiders and institutionals hold more shares of ALEC or SPRY?

Is ALEC or SPRY more profitable?

Which has more volatility & risk, ALEC or SPRY?

Which has preferable earnings & valuation, ALEC or SPRY?

Summary

How does Alector compare to MeiraGTx?

Is ALEC or MGTX more profitable?

Do institutionals & insiders believe in ALEC or MGTX?

Do analysts rate ALEC or MGTX?

Which has preferable earnings & valuation, ALEC or MGTX?

Does the media refer more to ALEC or MGTX?

Which has more risk & volatility, ALEC or MGTX?

Summary

How does Alector compare to Arbutus Biopharma?

Which has stronger valuation & earnings, ABUS or ALEC?

Does the media refer more to ABUS or ALEC?

Do analysts prefer ABUS or ALEC?

Is ABUS or ALEC more profitable?

Which has more risk & volatility, ABUS or ALEC?

Do insiders and institutionals have more ownership in ABUS or ALEC?

Summary

How does Alector compare to Janux Therapeutics?

Does the media favor JANX or ALEC?

Do institutionals & insiders hold more shares of JANX or ALEC?

Which has more volatility and risk, JANX or ALEC?

Do analysts rate JANX or ALEC?

Is JANX or ALEC more profitable?

Which has preferable earnings and valuation, JANX or ALEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools